Renovis (RNVS) fell from $14 to $3 (75%) back in October on cancellation of AstraZeneca trials. It has been trading in a tight range since, but rose 10% on Thursday and Friday on decent volume. They are presenting at a conference tomorrow: Renovis to Present at the Cowen & Co. 27th Annual Health Care Conference Thursday March 8, 8:00 am ET SOUTH SAN FRANCISCO, Calif., March 8 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS - News) today announced that Corey S. Goodman, Ph.D., President and Chief Executive Officer, will present at the Cowen & Co. 27th Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 13 at 11:00 a.m. Eastern Daylight Time. To access the live webcast, please visit Renovis' homepage, http://www.renovis.com. An archived version of the webcast will be available in the same location for ninety days following the presentation. About Renovis Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on purinergic receptors for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury. Downside risk seems limited and with any good news, RNVS could see a huge pop. May be worth a play.